Everpar Advisors LLC Acquires New Stake in Humana Inc. (NYSE:HUM)

Everpar Advisors LLC bought a new stake in Humana Inc. (NYSE:HUM) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,408 shares of the insurance provider’s stock, valued at approximately $645,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rakuten Securities Inc. acquired a new stake in Humana during the fourth quarter worth approximately $25,000. Gradient Investments LLC increased its stake in Humana by 200.0% in the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 40 shares during the last quarter. Cetera Trust Company N.A purchased a new position in Humana during the fourth quarter worth about $28,000. Nvwm LLC boosted its stake in Humana by 41.0% in the 3rd quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock worth $42,000 after buying an additional 25 shares during the last quarter. Finally, Operose Advisors LLC purchased a new stake in Humana in the 3rd quarter valued at about $56,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Humana

In related news, Director Jorge S. Mesquita purchased 545 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were acquired at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the transaction, the director now owns 2,578 shares of the company’s stock, valued at $946,358.02. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.29% of the company’s stock.

Humana Stock Up 1.7 %

NYSE HUM traded up $5.40 during trading hours on Tuesday, reaching $324.63. 1,068,997 shares of the company traded hands, compared to its average volume of 1,975,113. The stock has a market capitalization of $39.12 billion, a PE ratio of 20.21, a PEG ratio of 1.86 and a beta of 0.49. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77. Humana Inc. has a 12 month low of $298.61 and a 12 month high of $541.21. The company has a 50 day moving average of $323.08 and a two-hundred day moving average of $385.94.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping the consensus estimate of $6.12 by $1.11. The business had revenue of $29.61 billion for the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter last year, the company posted $9.38 earnings per share. As a group, equities analysts expect that Humana Inc. will post 16.18 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.09%. Humana’s payout ratio is currently 22.04%.

Wall Street Analysts Forecast Growth

HUM has been the topic of a number of research analyst reports. Argus cut Humana from a “buy” rating to a “hold” rating in a report on Wednesday, March 13th. Deutsche Bank Aktiengesellschaft lowered shares of Humana from a “buy” rating to a “hold” rating and cut their price target for the company from $595.00 to $360.00 in a report on Thursday, January 25th. The Goldman Sachs Group decreased their price objective on shares of Humana from $450.00 to $385.00 and set a “buy” rating for the company in a research note on Wednesday, April 3rd. StockNews.com lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 26th. Finally, UBS Group reduced their target price on shares of Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, April 25th. Eleven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Humana has a consensus rating of “Hold” and a consensus price target of $424.50.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.